Absology
Latest round
- Series B
Last raised
- Dec 2023
Total raised
- $15M
Investors
- 7
About Absology
, formerly Intekbio Co., is a field diagnosis-based in vitro immune diagnostic device venture company providing an in-vitro-diagnostic system. Absology's product offering includes Absol, a POCT analyzer that enables its customer to perform test within 5 minutes or ultra-sensitive immunological tests within 30 minutes. The diagnostic test can be done for testosterone, Vitamin - D, PSA, freeT4, TSH and FT4 combo, PCT, cortisol, cardiac, COVID-19 IgM/IgG combo, COVID-19 Ag, COVID-19 NAb, and TSH & FT4 combo; Absolute HS is a high sensitivity ELISA analyzer for early disease screening and testing time takes about 40 minutes. The test can be perform for cardiovascular, Alzheimer's, and anti-cancer therapy monitoring.
Who invested in Absology
7 investors across 2 rounds
See all investors in Absology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Absology
Who invested in Absology?
Absology has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Absology raised?
Absology has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Absology last raise money?
Absology's most recent round on record is a Series B, in Dec 2023.
What does Absology do?
Absology is a medical devices & equipment company.
Where is Absology headquartered?
Absology is headquartered in Anyang-si, South Korea.
Which VCs invest in companies like Absology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back medical devices & equipment companies at Absology's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series B
Raising like Absology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.